255 related articles for article (PubMed ID: 22983919)
1. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.
Stoetzer OJ; Fersching DM; Salat C; Steinkohl O; Gabka CJ; Hamann U; Braun M; Feller AM; Heinemann V; Siegele B; Nagel D; Holdenrieder S
Tumour Biol; 2013 Feb; 34(1):81-90. PubMed ID: 22983919
[TBL] [Abstract][Full Text] [Related]
2. Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin.
Stoetzer OJ; Fersching DM; Salat C; Steinkohl O; Gabka CJ; Hamann U; Braun M; Feller AM; Heinemann V; Siegele B; Nagel D; Holdenrieder S
Cancer Lett; 2013 Aug; 336(1):140-8. PubMed ID: 23612068
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy.
Exner R; Sachet M; Arnold T; Zinn-Zinnenburg M; Michlmayr A; Dubsky P; Bartsch R; Steger G; Gnant M; Bergmann M; Bachleitner-Hofmann T; Oehler R
Cancer Med; 2016 Sep; 5(9):2350-8. PubMed ID: 27457217
[TBL] [Abstract][Full Text] [Related]
4. High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy.
Fujimoto Y; Higuchi T; Nishimukai A; Miyagawa Y; Kira A; Ozawa H; Bun A; Imamura M; Miyoshi Y
J Surg Oncol; 2018 Jul; 118(1):228-237. PubMed ID: 29936704
[TBL] [Abstract][Full Text] [Related]
5. Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy.
Lehner J; Stötzer OJ; Fersching D; Nagel D; Holdenrieder S
Clin Chim Acta; 2013 Oct; 425():206-11. PubMed ID: 23916787
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
7. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients.
Bao H; Yu D; Wang J; Qiu T; Yang J; Wang L
Anticancer Drugs; 2008 Mar; 19(3):317-23. PubMed ID: 18510179
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy.
Kohles N; Nagel D; Jüngst D; Stieber P; Holdenrieder S
Tumour Biol; 2012 Dec; 33(6):2401-9. PubMed ID: 22965881
[TBL] [Abstract][Full Text] [Related]
10. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients.
Fahmueller YN; Nagel D; Hoffmann RT; Tatsch K; Jakobs T; Stieber P; Holdenrieder S
Int J Cancer; 2013 May; 132(10):2349-58. PubMed ID: 23047645
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic relevance of plasma DNA and DNA integrity for breast cancer.
Stötzer OJ; Lehner J; Fersching-Gierlich D; Nagel D; Holdenrieder S
Tumour Biol; 2014 Feb; 35(2):1183-91. PubMed ID: 24018822
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis-related biomarkers sFAS, MIF, ICAM-1 and PAI-1 in serum of breast cancer patients undergoing neoadjuvant chemotherapy.
Fersching DM; Nagel D; Siegele B; Salat C; Heinemann V; Holdenrieder S; Stoetzer OJ
Anticancer Res; 2012 May; 32(5):2047-58. PubMed ID: 22593487
[TBL] [Abstract][Full Text] [Related]
13. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy.
Wittwer C; Boeck S; Heinemann V; Haas M; Stieber P; Nagel D; Holdenrieder S
Int J Cancer; 2013 Dec; 133(11):2619-30. PubMed ID: 23729200
[TBL] [Abstract][Full Text] [Related]
14. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
17. An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.
Perrier A; Boelle PY; Chrétien Y; Gligorov J; Lotz JP; Brault D; Comperat E; Lefèvre G; Boissan M
PLoS One; 2020; 15(1):e0227356. PubMed ID: 31910438
[TBL] [Abstract][Full Text] [Related]
18. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety analysis of paclitaxel liposome and docetaxel for the neoadjuvant chemotherapy of breast cancer].
Su W; Zhang S; Li C; Hao X; Zhang J
Zhonghua Zhong Liu Za Zhi; 2015 May; 37(5):379-82. PubMed ID: 26463031
[TBL] [Abstract][Full Text] [Related]
20. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
Schneeweiss A; Chia S; Hickish T; Harvey V; Eniu A; Hegg R; Tausch C; Seo JH; Tsai YF; Ratnayake J; McNally V; Ross G; Cortés J
Ann Oncol; 2013 Sep; 24(9):2278-84. PubMed ID: 23704196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]